ESR1 and breast cancer: Therefore, compounds that modulate ERα activity are considered potential anti-breast cancer drug candidates, whose biological activity is often assessed by their half-maximal inhibitory concentration (IC50), where lower IC50 values indicate stronger inhibitory effects.